Want to see HK:1167 full AI Analyst Report?
Jacobio Pharmaceuticals Group Co., Ltd. (1167) AI Stock Analysis
Jacobio Pharmaceuticals Group Co., Ltd.
(HKEX:1167)
Overall score is held back primarily by weak financial performance—sharp revenue decline, ongoing losses, and sustained negative free cash flow implying continued funding sensitivity. Technicals provide a modest offset with improving near-term trend and neutral-to-positive momentum, while valuation is supportive on a low P/E but lacks dividend yield support.
Jacobio Pharmaceuticals Group Co., Ltd. (1167) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 3.60B
- Dividend Yield
- ―
- Average Volume (3M)
- 2.35M
- Price to Earnings (P/E)
- 6.0
- Beta (1Y)
- 0.74
- Revenue Growth
- 286.20%
- EPS Growth
- ―
- Country
- Hong Kong
- Employees
- 207
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Jacobio Pharmaceuticals Group Co., Ltd. Business Overview & Revenue Model
Company Description
Jacobio Pharmaceuticals Group Co., Ltd. is a clinical-stage pharmaceutical firm specializing in the proprietary discovery and development of oncology therapies. Its primary drug development initiatives feature two clinical-stage allosteric Src homolo...
How the Company Makes Money
Jacobio’s revenue model is primarily based on monetizing its drug discovery and development capabilities and the value of its clinical pipeline. Key revenue streams typically include: (1) collaboration and licensing income, where the company may out-...
Jacobio Pharmaceuticals Group Co., Ltd. Financial Statement Overview
Summary
Financials are pressured by a sharp 2025 revenue contraction (~74% vs. 2024), persistent operating/net losses, and recurring negative operating/free cash flow with higher 2025 cash burn. A positive offset is manageable leverage (debt-to-equity ~0.16–0.21), but declining equity and consistently negative ROE indicate ongoing dilution/funding risk if losses persist.
Income Statement
24NegativeBalance Sheet
62PositiveCash Flow
30Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 728.51M | 52.14M | 155.71M | 63.52M | 95.75M | 152.81M |
| Gross Profit | 687.70M | 29.35M | 155.71M | 3.20M | 12.63M | 12.83M |
| EBITDA | 513.83M | -142.87M | -176.73M | -325.73M | -355.80M | -289.83M |
| Net Income | 506.80M | -142.20M | -155.71M | -359.12M | -371.86M | -301.19M |
Balance Sheet | ||||||
| Total Assets | 1.86B | 1.30B | 1.36B | 1.46B | 1.57B | 1.72B |
| Cash, Cash Equivalents and Short-Term Investments | 1.68B | 1.10B | 1.17B | 1.15B | 1.28B | 1.54B |
| Total Debt | 159.78M | 165.24M | 152.08M | 209.91M | 147.79M | 6.81M |
| Total Liabilities | 511.70M | 533.92M | 435.99M | 387.11M | 292.12M | 84.75M |
| Stockholders Equity | 1.35B | 770.96M | 923.18M | 1.07B | 1.28B | 1.64B |
Cash Flow | ||||||
| Free Cash Flow | 544.99M | -187.27M | -86.21M | -402.86M | -308.92M | -158.63M |
| Operating Cash Flow | 546.02M | -186.20M | -74.12M | -364.20M | -292.42M | -147.49M |
| Investing Cash Flow | -832.29M | -138.63M | 256.22M | -48.00M | -686.32M | 161.67M |
| Financing Cash Flow | -15.60M | 45.20M | 21.28M | 246.28M | -9.85M | 109.06M |
Jacobio Pharmaceuticals Group Co., Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1167, the sentiment is Negative. The current price of 4.60 is below the 20-day moving average (MA) of 5.31, below the 50-day MA of 5.70, and below the 200-day MA of 5.84, indicating a bearish trend. The MACD of -0.30 indicates Positive momentum. The RSI at 31.56 is Neutral, neither overbought nor oversold. The STOCH value of 8.06 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1167.
Jacobio Pharmaceuticals Group Co., Ltd. Peers Comparison
Overall Rating
HK:699870Outperform
HK:996652Neutral- HK:116752Neutral
HK:685550.1Neutral
HK:699648Neutral
HK:261646.6Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:6998 | 70Outperform | HKD 3.26B | 4.48 | 10.99% | ― | 1417.68% | 660.14% |
| HK:9966 | 52Neutral | HKD 6.06B | -30.68 | -10.27% | ― | -31.77% | -177.01% |
| HK:1167 | 52Neutral | HKD 3.62B | 6.00 | 47.76% | ― | 286.20% | ― |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:6855 | 50Neutral | HKD 10.12B | -5.93 | -153.78% | ― | 70.26% | -12.79% |
| HK:6996 | 48Neutral | HKD 1.80B | 29.59 | 6.51% | ― | 605.95% | ― |
| HK:2616 | 47Neutral | HKD 7.77B | -15.53 | -43.54% | ― | 116.67% | -0.42% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:1167 | Jacobio Pharmaceuticals Group Co., Ltd. | 4.60 | -2.66 | -36.64% | |
| HK:6996 | Antengene Corporation Limited | 2.79 | -2.33 | -45.51% | |
| HK:6998 | Genor Biopharma Holdings Limited | 1.62 | -1.51 | -48.24% | |
| HK:9966 | Alphamab Oncology | 6.21 | -5.46 | -46.79% | |
| HK:2616 | CStone Pharmaceuticals | 4.94 | -1.28 | -20.58% | |
| HK:6855 | Ascentage Pharma Group International | 27.20 | -40.70 | -59.94% |
Jacobio Pharmaceuticals Group Co., Ltd. Corporate Events
Jacobio Advances KRAS Oncology Pipeline as Glecirasib Gains Traction in China
Jacobio Pharmaceuticals reported interim results marked by continued progress in its oncology pipeline, led by glecirasib and sitneprotafib for KRAS G12C-mutated cancers. Glecirasib monotherapy has secured Chinese approval for second-line NSCLC, ente...
Jacobio Pharmaceuticals Sets Board Meeting to Approve Interim 2026 Results
Jacobio Pharmaceuticals has scheduled a board meeting for August 24, 2026 to review and approve its interim financial results for the six months ended June 30, 2026. The board will also consider publication of these results and address any other corp...
Jacobio Pharmaceuticals Forecasts First Interim Profit on Licensing-Driven Revenue Surge
Jacobio Pharmaceuticals reported that it expects to achieve its first-ever net profit of at least RMB600 million for the six months ended June 30, 2026, reversing a net loss of about RMB59 million a year earlier. The turnaround is driven by strong re...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 26, 2026